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The cytochrome P450-dependent monooxygenases play a central role in the metabolism of chemical
carcinogens. The action ofthese enzymes can lead to eithercarcinogen detoxication oractivation. Differences
in P450 expression in animal modelsgive rise to large differences in susceptibility to chemical carcinogens, so
genetic polymorphisms in P450 expression may be expected to be an important factor in individual human
susceptibility to cancer. Of particular interest is the genetic polymorphism at the cytochrome P450-
debrisoquine/sparteine hydroxylase locus (CYP2D6). Although this is a minor liver P450, its polymorphic
expression is associated with the abnormal metabolism ofat least 30 therapeutic drugs, including P-blockers
and tricyclic antidepressants. Conflicting reports have been made on the association of this polymorphism
with cancersusceptibility. Thisdisagreement maybeattributable tolimitations ofthephenotypingassayused
to identify affected individuals (poor metabolizers, PMs). In order to clarify these anomalies, we have
developed a simple DNA-based assay with which we can identify the majority of PMs. The assay is centered
aroundthe primary gene defectresponsible forthepolymorphism, aG toAtransition atthejunction ofintron
3/exon 4 which results in a frame-shift in the resultant mRNA. The frequency ofthis mutation is 70-80% in
PMs. We have studied the frequency ofmutated alleles in a control population and in a wide range ofcancer
patients. No association between this polymorphism and lung cancer susceptibility was observed; however, in
other populations of cancer patients some very interesting shifts were found in the proportion of PMs and
heterozygotes from that in the normal population.
Introduction
Understanding the genetic factors that may affect the
susceptibility of an individual to disease orthe side effects
of drugs is of enormous value for predicting risk groups
and for the treatment of specific disorders. It has been
suggested that many cancers are initiated by either
environmental carcinogens or carcinogens generated by
our industrial environment (1). The cytochrome P450
monooxygenases play a central role in the metabolism of
such foreign compounds, and on this basis and their poly-
morphic expression, they may be an important factor in
assessing susceptibility to disease (2).
The P450-debrisoquine hydroxylase polymorphism in
humansis one ofthebest-studied enzyme deficiencies, and
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ithas beenvariously linked with different types ofcancer,
includingthose ofthelung(3-5),bladder(6) andbreast(7).
This polymorphism is characterized by the inability of
certain individuals to metabolize specific drugs (e.g.,
debrisoquine, sparteine, and bufuralol); and affected indi-
viduals, termed poormetabolizers (PMs), are known to be
deficient in the minor liver enzyme P450-CYP2D6 (8),
which is responsible for the metabolism of these com-
pounds. The PM phenotype is inherited in an autosomal
recessive manner in 5-10% of the Caucasian population
and is now associated with the inefficient metabolism of
over 30 drugs with a wide range of clinical indications
(9,10).
Most studies to date on the association ofthe CYP2D6
polymorphism with cancer have relied on phenotyping
assays which require administration of a test drug to
subjects followed by urine collection for several hours to
determine the concentration of unchanged drug, 4-
hydroxy metabolite, and hence metabolic ratio (11). There
are certain limitations to this assay, such as drug-drug
interactions, hormonal effects, effects ofthe disease state,
and the inability to identify heterozygotes. The develop-SMITH ET AL.
ment ofareliable DNA-based genetic assay to predict the
PM phenotype is thus essential for more comprehensive
studyofits associationwith disease susceptibility andthe
prediction ofindividuals at risk from drug side effects.
The CYP2D locus in humans has been identified as an
array ofat least three highlyhomologous gene sequences
onthelongarmofchromosome22.Inadditiontotheactive
CYP2D6 gene, an inactive pseudogene, CYP2D8P, and an
inactive homolog, CYP2D7 are present in a tandem array
(12). There is mounting evidence for the existence of a
fourth gene, CYP2D9, but it has not been fully charac-
terized to date (13). In initial experiments on genomic
DNA, restriction fragment length polymorphisms were
identified which could be associated with the PM phe-
notype; however these were found to be informative for
less than 25% of PM individuals (14). Isolation of DNA
clonesassociatedwiththenormalandmutantallelesofthe
CYP2D6 gene and subsequent sequence comparisons
allowedidentification ofthreemutations which explainthe
lack ofenzyme in 90% ofPM individuals (15-17). We have
developed a polymerase chain reaction (PCR)-based
genetic assay around one ofthese mutations,which allows
the identification ofapproximately 70-80% ofPMs (16). In
the work presented here, we screened over 2500 subjects
using this assay to determine whether any association
existsbetweenthedebrisoquine polymorphismandcancer
susceptibility.
Subjects and Methods
Sample Collection
Blood samples were collected from Caucasian indi-
viduals in EDTA or heparin vials from various locations
within the United Kingdom. The samples were either
frozen immediately or received at ambient temperature
and then stored at -20°C until required. Tissue samples
werefrozen as soonaspossibleafterexcisionandstored at
-700C prior to DNAisolation.
larget DNA Isolation
In some cases, genomic DNA was isolated from tissue
samples, whole blood, or lymphocyte preparations using
anAppliedBiosystems 340Anucleicacidextractoraccord-
ing to the manufacturer's instructions. Most blood sam-
ples were processed rapidly to provide crude cell extracts
suitableforPCRanalysis asfollows:Wholeblood (0.1 mL)
was thoroughly mixed (vortexed) with 0.75 mL of lOmM
Tris/HCl (pH 8), lmM EDTA (TE) in a microfuge tube
prior to centrifugation at 12,000g for20 sec. The superna-
tant was aspirated, and the pellet was further extracted
twicewith 0.5mL TE, as describedabove, tocomplete the
lysis of red blood cells and removal of plasma and other
contaminants that may affect the PCR reaction. The final
crude cell pellet (white blood cells) was lysed by the
addition of0.1 mL ofbufferA: 50mMKCI,2.5mMMgCl2,
20 mM Tris/HCl (pH 8), 0.45% Nonidet P-40, 0.45%
Tween-20; containing 200 ,ug/mL proteinase K. After
incubation at 55°C for 20 min, 0.1 mL ofsterile waterwas
added, andthelysatewasheatedto 90-100°C for10minto
inactivate the proteinase. This rapid procedure provides
sufficient lysate for 20-40 PCR analyses (13).
Polymerase Chain Reaction Analysis
Target DNA (1 ,ug genomic DNA or 5-10 ,uL crude
blood lysate) was amplified by polymerase chain reaction
[PCR (18)] using 300 ng of each CYP2D6-specific ampli-
ficationprimer(seelegendtoFig.1).ThePCRwascarried
outusing 2 U ofeitherAmplitaq DNApolymerase (Cetus
Corp.) or Hot-Tub DNA polymerase (Amersham PLC)
according to the manufacturers' instructions, except that
dimethyl sulfoxidewas added to 10% (v/v) final concentra-
tion when using Amplitaq. In a Techne model PHC-2
thermocycler,aninitialstrandseparationstepwascarried
out at 94°C (5 min) priorto 30-35 cycles ofstrand separa-
tion, 94°C (30 sec), primer annealing, 60°C (60 sec), and
polymerization, 72°C (60 sec). A final polymerization step
at 72°C was carried out to complete elongation of all
amplified strands. The high annealing temperature was
required in order that the primers used annealed only to
CYP2D6 sequences and nottothehomologous CYP2D7of
CYP2D8P genes (16).
To distinguish between CYP2D6 alleles, 30-40 pL1 of
the amplified mixture were digested using 10 U Bst Ni
(New England Biolabs) according to the manufacturer's
instructions, and fragments were separated by elec-
trophoresis through an 8% polyacrylamide/TBE (90 mM
Tris-borate [pH 8.3], 2 mM EDTA) gel (16). Bands were
visualized by ultraviolet irradiation of gels stained with
ethidium bromide.
Statistical Analysis ofResults
Differences in the distribution of assigned genotypes
between the random normal and cancer populations were
evaluated for significance using the two-tailed chi-square
test (19). Contingencytableswere constructed to compare
observed genotypes and phenotype with expected values
ofhomozygote and heterozygotes ofthe mutant and nor-
mal CYP2D6 alleles.
Results and Discussion
Three common mutations have been identified that can
explain the absence of a functional P450-CYP2D6 (de-
brisoquine hydroxylase) enzyme in the livers of PMs: a)
major deletions ofCYP2D6 coding sequences, accounting
forapproximately10% ofmutantalleles; b) anAdeletion at
nucleotide 2637 in exon 5 (14), which results in a frame-
shift and premature termination in mRNA, seen in
approximately 2-5% of mutant alleles; and c) a G to A
transition atthe intron 3/exon 4boundary ofthe CYP2D6
gene, which leads to incorrect splicing of the resultant
mRNA,resultingin aframe-shiftandprematuretermina-
tion. The G to A transition has been identified as the
primarygenedefectattheCYP2D6locusandisestimated
to account for 80-90% ofmutant alleles in PMs (16). This
siteisthefoundationoftheDNA-basedgeneticassayused
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inthisstudy.Theintron3/exon4junctionhasthesequence
CCCCCAG/GACGCC (bold letters indicating exon 4) in
the normal allele but CCCCCAAG/ACGCC in mutant
alleles. The mutation shifts the 3'-splice acceptor site
(italics) onebase pairdownstream, resultingintheloss of
the first nucleotide (Gin the normal allele) ofexon 4 and a
premature termination at position 544 of the mRNA
(14,17). The mutation also leads to the loss of a Bst Ni
restriction site (CCAGG to CC, AG).
Figure 1 shows a diagrammai representation of the
assayforthePMgenotype.PC-, amplificationofDNAand
subsequent digestion of the products, allows assignment
of an individual's CYP2D6 genotype with respect to the
intron 3/exon mutation within the gene. The diagnostic
pattern ofbands produced after gel electrophoresis cate-
gorizes an individual as follows: EM; carrying two wild-
type (normal) CYP2D6 alleles at the site of the G to A
mutation (almost exclusively extensive metabolizers), or
one normal allele and a deletion; HEM, heterozygous at
this site, i.e. carrying onewild-type and onemutantallele;
PM, poormetabolizers, carryingtwomutantalleles orone
mutant GtoAallele and agene deletion.We estimate that
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FIGURE 1. Polymerase chain reaction (PCR) assay for the G to A transition mutation at the intron 3/exon 4 junction of the CYP2D6 gene.
Diagrammatic representation ofthe method used and predicted banding patterns of individuals carrying the normal CYP2D6 allele (EM), mutant
CYP2D6 allele (PM), orboth(HEM). PCRamplification ofDNAusingprimerpairC (exon3: 5'-GCCTTCGCCAACCACTCCG-3') and D (intron 4: 5'-
AAATCCTGCTCTTCCGAGGC-3') results in afragment of334bp (Fl) spanningthe diagnostic polymorphicBstNi restriction enzyme site (CCNGG)
attheintron3/exon4boundary.Thisfragmentis digestedbyBstN1 into twobands of230bp(F2) and 105bp(F3) in samples obtainedfromindividuals
carrying the normal CYP2D6 allele, while the Fl fragment produced from the mutant allele is resistant to digestion. Primer D contains sequence
mismatches with the CYP2D8P and CYP2D7 genes.
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Table 1. Distribution ofCYP2D6 alleles in cancer patients.
No. of Genotype
Subjects/patients samples % EM % HEM % PM %MAFa 2 p<
Random controls 720 66.1 29.6 4.3 19.1 - -
Emphysema 151 61.6 35.1 3.3 20.9 2.35 0.50
All cancers 1759 63.4 31.6 5.0 20.8 6.38* 0.05
Lung cancerC 361 64.8 31.6 3.6 19.4 0.96 0.90
Breast cancer 437 66.8 29.3 3.9 18.5 0.22 0.90
Colon cancer 115 63.8 29.6 6.9 21.7 2.88 0.50
Leukemiad 312 65.7 26.9 7.4 20.8 7.65* 0.02
Teratomae 169 65.7 30.8 3.5 18.9 0.32 0.90
Melanoma 127 54.3 39.4 6.3 26.0 7.91* 0.02
Bladder cancer 184 53.8 41.8 4.4 25.3 13.50* 0.005
Prostate cancer 54 59.2 31.5 9.3 25.0 3.62 0.50
Abbreviations: EM, extensive metabolizer; HEM, heterozygous at site ofG to A mutation; PM, poor metabolizer.
aMutant allele frequency: proportion ofCYP2D6 alleles that carry the intron 3/exon 4 mutation.
bCalculated with two degrees offreedom.
cIncludes 145 squamous cell carcinomas, 74 adenocarcinomas, 52 small-cell lung cancers, and 90 other cancers (large-cell, mesothelioma, apical,
bronchogenic carcinomas) and unknowns.
dIncludes 141 cases ofacute myeloid, 117 cases ofchronic myeloid, 37 cases ofmyelodysplastic syndrome, and 17 cases ofother leukemic disorders.
eIncludes data obtained from teratocarcinoma and seminoma patients.
*Statistically significant.
we canidentify80% ofallPMindividualsinthismannerin
anygivenpopulation (16).Asmallproportion ofindividuals
homozygous or heterozygous for the G to A mutation will
be PMs because they carry the base-pair deletion in exon
5; however, this will not affect the comparison of the
frequency of mutant alleles in normal and cancer patient
populations, described below.
Table 1 and Figure 2 summarize the results of the
screening ofover 2500 individuals for the major mutation
in CYP2D6. The distribution of apparent EMs, HEMs,
and PMs in a random population ofCaucasians (n = 720)
was 66.1, 29.6, and 4.3%, respectively. Within this group,
results of genotyping in control populations in Sheffield
(206) and Edinburgh (366)were combinedwith regionally
random samples obtained mainly from the ICRF, Clare
Hall Laboratories. The apparent proportions of PMs in
these separate control groups were 4.9, 3.8, and 4.7%,
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respectively. The frequency ofthe G to A mutant allele in
the population, calculated from the proportion of hetero-
zygotes and assuming two mutant alleles in PMs, was
19.1% of all CYP2D6 alleles. On this basis, it would be
predicted that 4% of the population are homozygous for
this allele. The proportion ofgenotyped PMs in this con-
trol population is slightly less than the expected number
(5-10%), often observed using the phenotyping assay. If
this assay can predict 80% of PMs, however, then the
observed value represents a PM proportion of 5.5-6% in
the Caucasian population, in good agreement with pre-
vious reports (9,10).
Ifwe considerthe distribution ofCYP2D6 genotypes in
all the cancer patients studied (1759 individuals), statis-
tically significant shifts were observed in the proportions
ofEMs, HEMs and PMs comparedwith the control popu-
lation (Table 1). This deviation can be attributed, however,
LO * EMPHYSEMA
_ ALLCANCERS
- LUNGCANCER
0 BREAST CANCER
o3 COLON CANCER
* LEUKEMIA
.* TERATOMA
_ , __110 MELANOMA
El BLADDERCANCER
o3 PROSTATECANCER
FIGURE 2. Differencesinthedistributionofpoormetabolizers(PM)amongcancerpatients. Diagramshowsthedifferencefromcontroloftheproportion
ofPMs determined in each cancer cohort. The percentage PM distributions shown in Table 1 were comparedbysubtractingthe percentage PM in the
control population. The differences are shown as +/- differences ofthe population over that seen in the control (0).
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to an increasein mutant allele frequency asthe difference
between PMs and EMs is not significant (all mutant
alleles, x2 = 6.38, p < 0.05, homozygous G to A,
x2 =2.13, p < 0.5), and the overall proportion of PMs is
only slightly higher than that observed in the control
population (Fig. 2). This association, although statistically
significant, does not appear to have any biological rele-
vance. Interestingly, the frequency of HEMs among the
melanoma and bladder cancer patients was also signifi-
cantlyhigherthaninthecontrolpopulation (Table1);anda
relatively high (50% increased) PM frequency (6.3%) was
observedamongmelanomapatientsbutnotamongbladder
cancer patients, in whom the proportion of PMs was
almost identical to that in the control group (Fig. 2). In
melanoma and in bladder cancers, the mutant allele fre-
quency of approximately 25% was significantly greater
than that in controls. Why heterozygotes (in addition to
PMs) have an altered susceptibility to these diseases
requires further study.
In the series oflung cancer patients, there was a very
slight reduction in the proportion ofPMs (Fig. 2) but the
observed change in CYP2D6 genotype distribution was
not statistically significant (Table 1). Interestingly, a vir-
tually identical reduction in the proportion of PMs was
observed in the emphysema cohort (Table 1 and Fig. 2).
Emphysema patients have been used as a direct control
group in previous studies associating debrisoquine
hydroxylation phenotype with lung cancer (3,20). In addi-
tion, no difference from control was evident in mutant
allele frequency in lung cancer patients, but slight
increases in the mutant allele frequency and the propor-
tion of heterozygotes was observed in emphysema pa-
tients. The lung cancer data are in contrast with those
from studies inwhich greatlyreducedproportions ofPMs
were observed in lung cancer cohorts and a link was
suggested with the EM phenotype (3,4,20). In previous
studies, patients were phenotyped directly for debriso-
quinehydroxylase activityusingmarkerdrugs; therefore,
fundamental differences in the two types of assay may
account for the apparent anomaly. It must be emphasized
that phenotyping assays may be directly affected by the
disease stateoftheindividual andcomplicationsmayarise
fromthepharmaceutical andotherprocedures usedinthe
treatment of cancer patients. Such considerations are
irrelevant when using DNA-based genetic assays, even if,
as is the case here, only 80% of PMs can be predicted.
When the data on lung cancer are subdivided into the
tumor types, squamous-cell carcinomas and other smo-
king-related cancers (EM, 64.5%; HEM, 32%; PM, 3.5%;
n = 287) and adenocarcinoma (EM, 66.2%; HEM, 29.7%;
PM, 4.1%; n = 94), no significant reduction in the propor-
tion of PMs is observed (squamous-cell; x2 = 0.53,
p < 0.9), and the distribution of genotypes in cases of
adenocarcinoma ofthelungisvirtuallyidentical to thatin
the controlpopulation. Inviewofthe central role ofP450s
in the activation of carcinogens, an association between
the expression ofthese enzymes, including CYP2D6, and
lung cancer cannot be completely ruled out. They may be
implicated at some stagein tumorprogression, although it
appears unlikelythatthis is determined predominantly at
the genetic level.
Although slight reductions in the proportion of PMs
were observed in the teratoma/seminoma and breast can-
cercohorts (Fig.2)therewasnosignificantvariationfrom
normal ofthe distribution ofgenotypes and mutant allele
frequency in these two cancer groups (Table 1). In the
cohorts ofcolon cancerandprostate cancerpatients, there
is a relatively large increase in the proportion ofPMs, to
6.9% and 9.3%, respectively, although these did not reach
statistical significance. These increases may represent
somelevel ofriskassociatedwiththePM genotype, as the
apparent mutant allele frequency is substantially in-
creased in cases ofboth colon and prostate cancer. Many
more patients should be studied, however, especiallythose
with prostate cancer, to provide a clearer picture of the
extent ofcorrelation between these two cancer types and
the PM genotype.
The difference in distribution ofgenotypes in leukemic
patients relative tocontrolswashighlysignificant, with an
increase in the proportion of PMs (Fig. 2) and a slight
decreaseintheproportion ofheterozygotes (Table1). This
cohortincluded54individualswithpreleukemicmyelodys-
plastic syndrome and other lymphatic disorders (see foot-
notes to Table 1). When these are discounted and only
"true"leukemicdisorders (acutemyeloid, chronicmyeloid,
acute lymphocytic, chronic lymphocytic) are analysed, the
level ofstatistical significance is increased [n = 266: EM,
66.9%; HEM, 25.2%; PM, 7.9%: x2 = 9.62, p < 0.01 for
genotypes: X = 8.45, p < 0.005, for G to Ahomozygotes).
This suggests a strong association between the PM gen-
otype and leukemia. Itis known that many chemicals and
some anti-cancer agents can induce leukemia, but it is not
clear whether they are metabolized by CYP2D6. Alter-
natively, itis possible thatthe data obtained in this cancer
study could be better explained by linkage between
CYP2D6 and a gene involved in the pathogenesis of this
disease. Itisalreadyknownthatthec-sis(platelet-derived
growth factor B) proto-oncogene and thyroid-stimulating
hormonereceptorgene arelocated onchromosome 22 (21),
and we have recently mapped the CYP2D6 locus to
22q13.1, very closely linked with these two candidate
oncogenes (unpublished observation). As the DNA from
the leukemia cases was obtained from blast cells, the
increase in the proportion ofPMs and the slight decrease
in that ofheterozygotes could be due to allelic loss in this
region of chromosome 22. Translocations involving chro-
mosome22 areknowntobeinvolvedinthepathogenesis of
leukemia, although theypredominantly involve transloca-
tions around the c-abllocus. Thepossibilityofallelelossis
therefore worthy offurther study.
In summary, the data presented in this report suggest
thatthereisnoreductionintheproportionofPMsinmany
of the cancer types that have been previously associated
with the CYP2D6 polymorphism. It is thus unlikely, at
least at the genetic level, that the debrisoquine polymor-
phism is a susceptibilty factor in these diseases; however,
severalofthecancertypesstudiedshowedincreasesinthe
proportion of PMs and significant increases in the fre-
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quency of mutant alleles as a percentage of all CYP2D6
alleles. Inaddition, significant changes inthefrequencyof
heterozygotes were observed in certain cancer groups.
Several important questions regarding the CYP2D6
polymorphism remaintoberesolved. Theseinclude: a) the
relationship between different mutations within the gene.
Are theyindependent? b) isolation and characterization of
further genes in this gene cluster, e.g., CYP2D9. Do they
represent active genes? c) are some ofthe "pseudogenes"
foundin Caucasians active in otherracial groups? d) is the
CYP2D6geneinlinkagedisequilibriumwithanoncogene?
e) can substrates for CYP2D6 be found which are known
carcinogens?]) moreworkisrequired onthe association of
CYP2D6withotherenvironmentallylinkeddisorders,par-
ticularly neurological diseases, g) does CYP2D6 have an
importantphysiological function? h)howisCYP2D6regu-
lated? Consideration ofthese issues and continued studies
with DNA-based analysis ofthelocus shouldgiveaclearer
insight into the role ofP450s in cancer susceptibility.
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